Biotechnology News DEPAKENE Search

BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login

Search Results

Documents 1-3 out of 3 found

Current Search: depakene: 3

Second Messenger Systems, Genes, Neurogenesis, and Mood Disorders
For many years, research on mood disorders has focused on neurotransmitters, particularly on the monoamines (serotonin, norepinephrine, and dopamine) and their action at the neuronal junction, or synapse.

Although the monoamine theory...

Consultant Live: Jun 11 2008 7:11PM
Matching: depakene

Find similar documents

Epilepsy Drug Dilantin May Speed Bone Loss
-- Young women taking the common epilepsy drug Dilantin may risk bone loss and fracture with long-term use.

A new study shows young women taking phenytoin (also commonly known as Dilantin) for one year lost 2.6% of the bone density in the...

WebMD: May 1 2008 4:27AM
Matching: depakene

Find similar documents

Kyowa Hakko Fiscal 2007 Operating Income up 28.3%: Sales and Operating Income Exceed Plan Targets
- Kyowa Hakko Kogyo Co.

(Kyowa Hakko)(TOKYO:4151) today announced its consolidated financial results for the year ended March 31, 2008 (Fiscal 2007).

Consolidated net sales were JPY 392.1 billion, up 10.7% and consolidated operating...

Pharma Live: Apr 28 2008 11:54AM
Matching: depakene

Find similar documents

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright � 1997-2008 - BioPortfolio Limited.